New pill combo may boost CAR-T power against hard-to-treat lymphoma
NCT ID NCT07341191
First seen Jan 16, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This study is for people with mantle cell lymphoma that has come back or not responded to prior treatment. It tests whether adding two oral medications (sonrotoclax and zanubrutinib) to standard CAR-T cell therapy can improve how well the cancer responds. About 40 adults will take part, and researchers will track tumor shrinkage, survival, and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BCCA - Vancouver
NOT_YET_RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
Contact Phone: •••-•••-••••
-
University Health Network
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact
Conditions
Explore the condition pages connected to this study.